Journey Medical DERM
NASDAQ DERM
$6.49 +0.06 (+0.93%)
At close: Sep 29, 2026 · 4:00 PM EDT

Journey Medical (DERM) EBITDA Margin (2020)

Updated

Journey Medical's EBITDA Margin came in at -51.29% for FY2021, down 72.12 percentage points from 20.83% in FY2020.

Analysis

Journey Medical (DERM) EBITDA Margin (2020) Analysis & Trends

  • Per Business Quant, earlier years put EBITDA Margin at 20.83% in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 35.95%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 49.01%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 6.02%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 33.11%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 46.01%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 39.10%
10 Journey Medical 176.78 Mn 74.87 Mn 12.37 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 28.76%
Sep 30, 2020 6.77%
API Access

Journey Medical EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=DERM&period=max&api_key=YOUR_API_KEY